Breast Cancer Research and Treatment

, Volume 112, Supplement 1, pp 5–13 | Cite as

Treatment decision-making in breast cancer: the patient–doctor relationship

Optimizing Breast Cancer Patient

Abstract

A diagnosis of breast cancer, whether the disease is early or advanced, can be devastating. With this in mind, constructive patient–physician relationships are essential to minimizing disease-related stress and anxiety, as patients undergo treatment and learn to cope with their diagnosis. Good communication skills are vital, and achieve measurable benefits, yet doctors receive very little training in communication. Patients may find it difficult to process large amounts of information, may not understand medical terminology, and can become confused or scared during discussions. They may need time to absorb information, and discuss it with friends and family, before treatment decisions are made. Patient awareness of treatment options is greater than ever, largely because of media exposure and the internet. Consequently, patients’ expectations and desire to be involved in treatment choice are increasing, although some patients still prefer to leave decision-making to their doctor. Information about potential side-effects and other treatment burdens is vital, if patients are to make truly informed choices. Knowing in advance what side effects may be encountered, and how to manage them, can also help to improve adherence to treatment, which is necessary for patients to gain the maximum benefit. Side effects that patients find most problematic often differ from those that most concern doctors. Individual patients have different needs and expectations that must be respected, but ensuring that they understand their diagnosis, and the expected benefits and potential risks of treatment, is the key to establishing a good therapeutic relationship and providing the best possible care.

Keywords

Decision making Breast cancer Doctor–Patient relationship 

Notes

Financial disclosure/conflict of interest statement

The author of this article has no commercial associations (e.g., consultancies, stock ownership, equity interests, patentlicensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article. All funding sources supporting the work and all institutional or corporate affiliations of the author are acknowledged.

References

  1. 1.
    Fallowfield L, Jenkins V (1999) Effective communication skills are the key to good cancer care. Eur J Cancer 35:1592–1597PubMedCrossRefGoogle Scholar
  2. 2.
    Fallowfield L, Lipkin M, Hall A (1998) Teaching senior oncologists communication skills: results from phase I of a comprehensive longitudinal program in the United Kingdom. J Clin Oncol 16:1961–1968PubMedGoogle Scholar
  3. 3.
    Taylor C, Graham J, Potts HW et al (2005) Changes in mental health of UK hospital consultants since the mid-1990s. Lancet 366:742–744PubMedCrossRefGoogle Scholar
  4. 4.
    Fallowfield LJ (1995) Communication skills of oncologists. Trends Exper Med 5:99–103Google Scholar
  5. 5.
    Siminoff LA (1992) Improving communication with cancer patients. Oncology 6:83–87PubMedGoogle Scholar
  6. 6.
    Fallowfield L, McGurk R, Dixon M (2004) Same pain, less gain: potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer. Eur J Cancer 40:2403–2410PubMedCrossRefGoogle Scholar
  7. 7.
    Butler L, Bacon M, Carey M, Zee B, Tu D, Bezjak A (2004) Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J Clin Oncol 22:2461–2468PubMedCrossRefGoogle Scholar
  8. 8.
    Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM (2004) How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 22(17):3485–3490PubMedCrossRefGoogle Scholar
  9. 9.
  10. 10.
    Ries LAG, Melbert D, Krapcho M et al (2006). SEER Cancer Statistics Review, 1975–2004. National Cancer Institute, Bethesda, MD. Available via: http://seer.cancer.gov/csr/1975_2004. Cited 30 May 2007
  11. 11.
    Tracy GE (2004) Breast cancer–the disease many women fear the most. SDJ Med 57(4):148Google Scholar
  12. 12.
    Schenck-Gustafsson K (2007) Diagnosis of cardiovascular disease in women. Menopause Int 13:9–22CrossRefGoogle Scholar
  13. 13.
    Wen KY, Gustafson DH (2004) Needs assessment for cancer patients and their families. Health Qual Life Outcomes 2:11PubMedCrossRefGoogle Scholar
  14. 14.
    Cox A, Jenkins V, Catt S et al (2006) Information needs and experiences: an audit of UK cancer patients. Eur J Oncol Nurs 10:263–272PubMedCrossRefGoogle Scholar
  15. 15.
    Jenkins V, Fallowfield L, Saul J (2001) Information needs of patients with cancer: results from a large study in UK cancer centres. Br J Cancer 84:48–51PubMedCrossRefGoogle Scholar
  16. 16.
    Perry S, Kowalski TL, Chang CH (2007) Quality of life assessment in women with breast cancer: benefits, acceptability and utilization. Health Qual Life Outcomes 5:24–37PubMedCrossRefGoogle Scholar
  17. 17.
    Degner LF, Kristjanson LJ, Bowman D et al (1997) Information need and decisional preferences in women with breast cancer. JAMA 277:1485–1492PubMedCrossRefGoogle Scholar
  18. 18.
    Mandelblatt J, Kreling B, Figeuriedo M, Feng S (2006) What is the impact of shared decision making on treatment and outcomes for older women with breast cancer? J Clin Oncol 24:4908–4913PubMedCrossRefGoogle Scholar
  19. 19.
    Deber RB, Kraetschmer N, Urowitz S, Sharpe N (2007) Do people want to be autonomous patients? Preferred roles in treatment decision-making in several patient populations. Health Expect 10:248–258PubMedCrossRefGoogle Scholar
  20. 20.
    Wallberg B, Michelson H, Nystedt M et al (2000) Information needs and preferences for participation in treatment decisions among Swedish breast cancer patients. Acta Oncol 39:467–476PubMedCrossRefGoogle Scholar
  21. 21.
    Janz NK, Wren PA, Copeland LA et al (2004) Patient–physician concordance: preferences, perceptions, and factors influencing the breast cancer surgical decision. J Clin Oncol 22:3091–3098PubMedCrossRefGoogle Scholar
  22. 22.
    Lantz PM, Janz NK, Fagerlin A et al (2005) Satisfaction with surgery outcomes and the decision process in a population-based sample of women with breast cancer. Health Serv Res 40:745–767PubMedCrossRefGoogle Scholar
  23. 23.
    Sabo B, St-Jacques N, Rayson D (2007) The decision-making experience among women diagnosed with stage I and II breast cancer. Breast Cancer Res Treat 102:51–59PubMedCrossRefGoogle Scholar
  24. 24.
    Caldon LJM, Walters SJ, Reed MWR (2007) Changing trends in the decision-making preferences of women with early breast cancer. Br J Surg (in press). doi: 10.1002/bjs.5964
  25. 25.
    Beaver K, Booth K (2002) Information needs and decision-making preferences: comparing findings for gynecological, breast and colorectal cancer. Eur J Oncol Nursing 11:409–416CrossRefGoogle Scholar
  26. 26.
    Katz SJ, Hawley ST (2007) From policy to patients and back: surgical decision-making for patients with breast cancer. Health Aff (Millwood) 26:761–769CrossRefGoogle Scholar
  27. 27.
    Whelan T, Sawka C, Levine M et al (2003) Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. J Natl Cancer Inst 95:581–587PubMedCrossRefGoogle Scholar
  28. 28.
    Keating NL, Guadagnoli E, Landrum MB et al (2002) Treatment decision making in early-stage breast cancer: should surgeons match patients’ desired level of involvement? J Clin Oncol 20:1473–1479PubMedCrossRefGoogle Scholar
  29. 29.
    Fallowfield L (1997) Offering choice of surgical treatment to women with breast cancer. Patient Educ Couns 30(3):209–214PubMedCrossRefGoogle Scholar
  30. 30.
    Fallowfield LJ, Hall A, Maguire P, Baum M, A’Hern RP (1994) Psychological effects of being offered choice of surgery for breast cancer. Br Med J 309:448–454Google Scholar
  31. 31.
    Al-Ghazal SK, Fallowfield L, Blamey RW (2000) Comparison of psychological aspects and patient satisfaction following breast conserving surgery, simple mastectomy and breast reconstruction. Eur J Cancer 36:1938–1943PubMedCrossRefGoogle Scholar
  32. 32.
    Al-Ghazal SK, Fallowfield L, Blamey RW (1999) Does cosmetic outcome from treatment of primary breast cancer influence psychosocial morbidity? Eur J Surg Oncol 25:571–573PubMedCrossRefGoogle Scholar
  33. 33.
    Al-Ghazal SK, Sully L, Fallowfield L, Blamey RW (2000) The psychological impact of immediate rather than delayed breast reconstruction. Eur J Surg Oncol 26:17–19PubMedCrossRefGoogle Scholar
  34. 34.
    Atkins L, Fallowfield L (2006) Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer 42:2271–2276PubMedCrossRefGoogle Scholar
  35. 35.
    Fallowfield L (2005) Acceptance of adjuvant therapy and quality of life issues. Breast 14:612–616PubMedCrossRefGoogle Scholar
  36. 36.
    Peto R, Davies C, on behalf of the ATLAS Collaboration (2007) ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11500 women—preliminary results. Breast Cancer Res Treat 106 (suppl 1):abstract 48Google Scholar
  37. 37.
    Fallowfield L, Fleissig A, Edwards R, West A, Powles TJ, Howell A, Cuzick J (2001) Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol 19:1885–1892PubMedGoogle Scholar
  38. 38.
    Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602–606PubMedCrossRefGoogle Scholar
  39. 39.
    Cox AC, Fallowfield LJ (2007) After going through chemotherapy I can’t see another needle. Eur J Oncol Nurs 11:43–48PubMedCrossRefGoogle Scholar
  40. 40.
    Chlebowski RT, Geller ML (2006) Adherence to endocrine therapy for breast cancer. Oncology 71:1–9PubMedGoogle Scholar
  41. 41.
    Fellowes D, Fallowfield LJ, Saunders CM, Houghton J (2001) Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for ‘well-tolerated’ treatments? Breast Cancer Res Treat 66:73–81PubMedCrossRefGoogle Scholar
  42. 42.
    Cella D, Falowfield L, Barker P et al (2006) Quality of life of postmenopausal women in the ATAC (“Arimidex”, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for early breast cancer. Breast Cancer Res Treat 100:273–284PubMedCrossRefGoogle Scholar
  43. 43.
    Fallowfield L, Bliss JM, Porter LS et al (2006) Quality of life in the Intergroup Exemestane Study: a randomized trial of exemestane versus continued tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24:910–917PubMedCrossRefGoogle Scholar
  44. 44.
    Whelan TJ, Goss PE, Ingle JN et al (2005) Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 28:6931–6940CrossRefGoogle Scholar
  45. 45.
    Trialists’ Group ATAC (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer. First results of the ATAC randomized trial. Lancet 359:2131–2139Google Scholar
  46. 46.
    Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62PubMedCrossRefGoogle Scholar
  47. 47.
    Fallowfield L, Cella D, Cuzick J et al (2004) Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 22:4261–4271PubMedCrossRefGoogle Scholar
  48. 48.
    Coombes RC, Kilburn LS, Snowdon CF et al (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369:559–570PubMedCrossRefGoogle Scholar
  49. 49.
    Wengström Y, Aapro M, Leto di Priolo S, Cannon H, Georgiou V (2007) Patients’ knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study. Breast 16:462–468PubMedCrossRefGoogle Scholar
  50. 50.
    Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer. N Engl J Med 349:1793–1802PubMedCrossRefGoogle Scholar
  51. 51.
    Gaston CM, Mitchell G (2005) Information giving and decision-making in patients with advanced cancer: a cancer systematic review. Soc Sci Med 61:2252–2264PubMedCrossRefGoogle Scholar
  52. 52.
    Grunfeld EA, Maher EJ, Browne S et al (2006) Advanced breast cancer patients’ perceptions of desicion making for palliative chemotherapy. J Clin Oncol 24:1090–1098PubMedCrossRefGoogle Scholar
  53. 53.
    Graydon J, Galloway S, Palmer-Wickham S et al (1997) Information needs of women during early treatment for breast cancer. J Adv Nurs 26:59–64PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  1. 1.CRUK Psychosocial Oncology GroupUniversity of SussexFalmerUK

Personalised recommendations